Inhibin/activin-betaC subunit does not represent a prognostic parameter in human endometrial cancer

Archives of Gynecology and Obstetrics

Volumn 284, Issue 1, 2011, Pages 199-207

  Käufl, Stefanie D ^a   Kuhn, Christina ^a   Kunze, Susanne ^a   Shabani, Naim ^a,b   Brüning, Ansgar ^a   Friese, Klaus ^a   Mylonas, Ioannis ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Klinikum Neuperlach   (Germany)

Author keywords

Cancer; Endometrium; Immunohistochemistry; Inhibin betaC; Prognosis; Survival

Indexed keywords

ACTIVIN BETAC SUBUNIT; INHIBIN; INHIBIN BETAC SUBUNIT; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; HEMANGIOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GERMANY; HUMANS; INHIBIN-BETA SUBUNITS; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 79958826689     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-010-1614-y     Document Type: Article

References (46)

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366(9484): 491-505 (Pubitemid 41111699)
2. Prat J (2004) Prognostic parameters of endometrial carcinoma. Hum Pathol 35(6):649-662
3. Jereczek-Fossa B, Badzio A, Jassem J (1999) Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. Int J Gynecol Cancer 9(4):285-294 (Pubitemid 29399360)
4. Sayin NC, Varol FG, Yuce MA, Kaplan P, Ahmet N, Sut N, Gucer F (2009) Do routine preoperative imaging techniques facilitate the operation in endometrial cancer? Arch Gynecol Obstet 280(2):211-215. doi:10.1007/s00404-008-0893-z
5. Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444(3):213-223
6. Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K (2009) Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer 45(7):1304-1314. doi:S0959-8049(09)00002- 1[pii]10.1016/j.ejca.2009.01.008
7. Worbs S, Shabani N, Mayr D, Gingelmaier A, Makrigiannakis A, Kuhn C, Jeschke U, Kupka MS, Friese K, Mylonas I (2007) Expression of the inhibin/activin subunits (-alpha, -betaA and -betaB) in normal and carcinogenic endometrial tissue: possible immunohistochemical differentiation markers. Oncol Rep 17(1):97-104
8. Xia Y, Schneyer AL (2009) The biology of activin: recent advances in structure, regulation and function. J Endocrinol 202(1):1-12. doi:JOE-08-0549[pii]10.1677/JOE-08-0549
9. Vale W, Wiater E, Gray P, Harrison C, Bilezikjian L, Choe S (2004) Activins and inhibins and their signaling. Ann N Y Acad Sci 1038:142-147 (Pubitemid 40577455)
10. Risbridger GP, Ball EM, Wang H, Mellor SL, Peehl DM (2004) Re-evaluation of inhibin alpha subunit as a tumour suppressor in prostate cancer. Mol Cell Endocrinol 225(1-2):73-76 (Pubitemid 39297056)
11. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A (1992) Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360(6402):313-319 (Pubitemid 23000668)
12. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A (1994) Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 91(19):8817-8821
13. Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V, Friese K (2004) Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Gynecol Oncol 93(1):92-97 (Pubitemid 38429554)
14. Hötten G, Neidhardt H, Schneider C, Pohl J (1995) Cloning of a new member of the TGF-beta family: a putative new activin beta C chain. Biochem Biophys Res Commun 206(2):608-613
15. Fang J, Yin W, Smiley E, Wang SQ, Bonadio J (1996) Molecular cloning of the mouse activin beta E subunit gene. Biochem Biophys Res Commun 228(3):669-674 (Pubitemid 26421438)
16. Weissenbacher T, Bruning A, Kimmich T, Makovitzky J, Gingelmaier A, Mylonas I (2010) Immunohistochemical Labeling of the Inhibin/activin betaC subunit in normal human placental tissue and chorionic carcinoma cell lines. J Histochem Cytochem 58(8):751-757. doi:jhc.2010.956185[pii]10.1369/jhc.2010. 956185
17. Mylonas I, Shabani N, Vogl J, Makovitzky J, Kunze S, Kuhn C, Schulze S, Friese K, Jeschke U (2007) Inhibin/activin subunits are immunohistochemically expressed in complete and partial hydatidiform moles. Anticancer Res 27(4A):1995-2000 (Pubitemid 46954714)
18. Gingelmaier A, Bruning A, Kimmich T, Makovitzky J, Bergauer F, Schiessl B, Friese K, Mylonas I (2010) Inhibin/activin-betaE subunit is expressed in normal and pathological human placental tissue including chorionic carcinoma cell lines. Arch Gynecol Obstet. doi:10.1007/s00404-009-1340-5
19. Kimmich T, Bruning A, Kaufl SD, Makovitzky J, Kuhn C, Jeschke U, Friese K, Mylonas I (2010) Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line. Arch Gynecol Obstet 282(2):185-191. doi: 10.1007/s00404-009-1310-y
20. Käufl SD, Makovitzky J, Kuhn C, Kunze S, Jeschke U, Mylonas I (2010) Inhibin/activin-betaC subunit in human endometrial adenocarcinomas and HEC-1a adenocarcinoma cell line. In Vivo (in press)
21. Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I (2007) Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 43(16):2434-2444. doi:S0959-8049(07)00642-9[pii]10.1016/j.ejca.2007.08. 014
22. Anonymous (1989) FIGO stages (announcements). Gynecol Oncol 35125-35127
23. Mylonas I, Jeschke U, Wiest I, Hoeing A, Vogl J, Shabani N, Kuhn C, Schulze S, Kupka MS, Friese K (2004) Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem Cell Biol 122(5):461-471 (Pubitemid 40379015)
24. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53457-53481
25. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34187-34220
26. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, Ogata E, Miyazono K, Shimizu K, Imamura T (2007) Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98(1):127-133 (Pubitemid 44803931)
27. Ogino H, Yano S, Kakiuchi S, Muguruma H, Ikuta K, Hanibuchi M, Uehara H, Tsuchida K, Sugino H, Sone S (2008) Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res 14(3):660-667 (Pubitemid 351231145)
28. Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H, Inokuchi K (2009) Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 7:15. doi: 1478-811X-7-15[pii]10.1186/1478-811X-7-15
29. Mylonas I, Jeschke U, Winkler L, Makovitzky J, Richter DU, Briese V, Friese K (2003) Immunohistochemical expression of inhibin-alpha in human endometrium and the in vitro secretion of inhibin, estradiol and cortisol in cultured human endometrial glandular cells. Arch Gynecol Obstet 268(3):142-150. doi: 10.1007/s00404-003-0526-5 (Pubitemid 36988445)
30. Vogl J, Hoing A, Schulze S, Kuhn C, Wiest I, Shabani N, Jeschke U, Mylonas I, Friese K (2007) Expression of inhibins in the endometrial carcinoma cell line RL-95-2 after stimulation with cortisol and estradiol. Anticancer Res 27(4A):1989-1993 (Pubitemid 46954713)
31. Mylonas I, Makovitzky J, Fernow A, Richter DU, Jeschke U, Briese V, Gerber B, Friese K (2005) Expression of the inhibin/ activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps. Arch Gynecol Obstet 272(1):59-66. doi:10.1007/s00404-004-0666-2 (Pubitemid 40896637)
32. Risbridger GP, Schmitt JF, Robertson DM (2001) Activins and inhibins in endocrine and other tumors. Endocr Rev 22(6):836-858 (Pubitemid 34214298)
33. Mylonas I (2010) Inhibin-alpha, -betaA and -betaB subunits in uterine non-endometrioid carcinomas: prognostic significance and clinical implications. Eur J Cancer. doi:S0959-8049(10)00476-4[pii]10.1016/j.ejca.2010.06.001
34. Sharifi N, Lechleider RJ, Farrar WL (2007) Transforming growth factor-beta receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate? J Mol Endocrinol 39(5):329-332
35. Chabicovsky M, Herkner K, Rossmanith W (2003) Overexpression of activin beta(C) or activin beta(E) in the mouse liver inhibits regenerative deoxyribonucleic acid synthesis of hepatic cells. Endocrinology 144(8):3497-3504 (Pubitemid 36904428)
36. Vejda S, Erlach N, Peter B, Drucker C, Rossmanith W, Pohl J, Schulte-Hermann R, Grusch M (2003) Expression of activins C and E induces apoptosis in human and rat hepatoma cells. Carcinogenesis 24(11):1801-1809 (Pubitemid 37408144)
37. Wada W, Medina JJ, Kuwano H, Kojima I (2005) Comparison of the function of the beta(C) and beta(E) subunits of activin in AML12 hepatocytes. Endocr J 52(2):169-175 (Pubitemid 40745702)
38. Gold EJ, Zhang X, Wheatley AM, Mellor SL, Cranfield M, Risbridger GP, Groome NP, Fleming JS (2005) betaA- and betaC-activin, follistatin, activin receptor mRNA and betaCactivin peptide expression during rat liver regeneration. J Mol Endocrinol 34(2):505-515 (Pubitemid 40585198)
39. Lau AL, Kumar TR, Nishimori K, Bonadio J, Matzuk MM (2000) Activin betaC and betaE genes are not essential for mouse liver growth, differentiation, and regeneration. Mol Cell Biol 20(16):6127-6137 (Pubitemid 30613060)
40. Gold E, Jetly N, O'Bryan MK, Meachem S, Srinivasan D, Behuria S, Sanchez-Partida LG, Woodruff T, Hedwards S, Wang H, McDougall H, Casey V, Niranjan B, Patella S, Risbridger G (2009) Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo. Am J Pathol 174(1):184-195. doi:ajpath.2009.080296[pii]10.2353/ajpath.2009.080296
41. Mellor SL, Cranfield M, Ries R, Pedersen J, Cancilla B, de Kretser D, Groome NP, Mason AJ, Risbridger GP (2000) Localization of activin beta(A)-, beta(B)-, and beta(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of beta(C)-subunit. J Clin Endocrinol Metab 85(12):4851-4858
42. Mellor SL, Ball EM, O'Connor AE, Ethier JF, Cranfield M, Schmitt JF, Phillips DJ, Groome NP, Risbridger GP (2003) Activin betaC-subunit heterodimers provide a new mechanism of regulating activin levels in the prostate. Endocrinology 144(10): 4410-4419 (Pubitemid 37204840)
43. Razanajaona D, Joguet S, Ay AS, Treilleux I, Goddard-Leon S, Bartholin L, Rimokh R (2007) Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res 67(15):7223-7229 (Pubitemid 47206550)
44. Ramachandran A, Marshall ES, Love DR, Baguley BC, Shelling AN (2009) Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett 285(2):157-165. doi:S0304-3835(09)00344-9[pii]10.1016/j.canlet.2009.05.010
45. Katik I, Mackenzie-Kludas C, Nicholls C, Jiang FX, Zhou S, Li H, Liu JP (2009) Activin inhibits telomerase activity in cancer. Biochem Biophys Res Commun 389(4):668-672. doi:S0006-291X(09)01857-9[pii]10.1016/j.bbrc.2009.09.055
46. Di Simone N, Schneyer AL, Caliandro D, Castellani R, Caruso A (2002) Regulation of endometrial adenocarcinoma cell proliferation by Activin-A and its modulation by 17beta-estradiol. Mol Cell Endocrinol 192(1-2):187-195 (Pubitemid 34667236)